Management of hypertension in peripheral arterial disease : does the choice of drugs matter?
Singer, Donald R. J. and Kite, A.. (2008) Management of hypertension in peripheral arterial disease : does the choice of drugs matter? European Journal of Vascular and Endovascular Surgery, Vol.35 (No.6). pp. 701-708. ISSN 1078-5884Full text not available from this repository.
Official URL: http://dx.doi.org/10.1016/j.ejvs.2008.01.007
Cardiovascular disease and death are major life-threatening problems in patients with atheromatous peripheral arterial disease (PAD). This review focuses on management of hypertension in the context Of cardiovascular risk in patients with PAD. PAD is underdiagnosed and hypertension in PAD is often poorly managed. Current evidence supports a low threshold for blood pressure treatment in PAD and intensive blood pressure control to reduce the high risk of cardiovascular disease and death in patients with PAD. Optimal treatment targets should be < 140185 mmHg, with the lower target of < 130/80 mmHg in the presence of diabetes mellitus or chronic renal disease. Class-specific selection of anti-hypertensive treatments in PAD should be based on caution in relation to co-existing renovascular disease and indications and contraindications based on other significant co-morbidity. There is a pressing need for primary end-point studies targeted specifically at patients with PAD. In particular, prospective studies in PAD are needed to obtain evidence for benefits from specific blood pressure classes of treatment as well as the optimal blood pressure treatment target level. These studies should consider impact in PAD of different demographic, risk factor, and co-morbidity profiles. (c) 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RC Internal medicine|
|Divisions:||Faculty of Medicine > Warwick Medical School > Clinical Sciences Research Institute (CSRI)
Faculty of Medicine > Warwick Medical School > Metabolic and Vascular Health
Faculty of Medicine > Warwick Medical School
|Library of Congress Subject Headings (LCSH):||Hypertension -- Treatment, Peripheral vascular diseases -- Risk factors, Cardiovascular system -- Diseases -- Risk factors|
|Journal or Publication Title:||European Journal of Vascular and Endovascular Surgery|
|Number of Pages:||8|
|Page Range:||pp. 701-708|
|Access rights to Published version:||Restricted or Subscription Access|
|References:||1 LIP GY, MAKIN AJ. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2003;(4):CD003075. 2 The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413e2446. 3 FERINGA HH, VAN WANING VH, BAX JJ, ELHENDY A, BOERSMA E, SCHOUTEN O et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006;47:1182e1187. 4 FERINGA HH, KARAGIANNIS SE, CHONCHOL M, VIDAKOVIC R, NOORDZIJ PG, ELHENDY A et al. Lower progression rate of endstage renal disease in patients with peripheral arterial disease using statins or angiotensin converting enzyme inhibitors. J Am Soc Nephrol 2007;18:1872e1879. 5 HIRSCH AT, CRIQUI MH, TREAT-JACOBSON D, REGENSTEINER JG, CREAGER MA, OLIN JW et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317e 1324. 6 OSTCHEGA Y, PAULOSE-RAM R, DILLON CF, GU Q, HUGHES JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999e2004. J Am Geriatr Soc 2007;55:583e 589. 7 MEIJER WT, GROBBEE DE, HUNINK MG, HOFMAN A, HOES AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med 2000;160:2934e2938. 8 KULLO IJ, BAILEY KR, KARDIAD SLR, MOSLEY Jr TH, BOERWINKLE E, TURNER ST. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vasc Med 2003;8:237e242. 9 MISSOURIS CG, BUCKENHAM T, CAPPUCCIO FP, MACGREGOR GA. Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. Am J Med 1994;96:10e14. 10 WACHTELL K, IBSEN H, OLSEN MH, LAYBOURN C, CHRISTOFFERSEN JK, NØRGAARD H et al. Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension. J Hum Hypertens 1996;10:83e85. 11 OZKAN U, OGUZKURT L, TERCAN F, NURSAL TZ. The prevalence and clinical predictors of incidental atherosclerotic renal artery stenosis. Eur J Radiol 2007 Dec 3 [epub ahead of print]. 12 BECKMAN JA, CREAGER MA, LIBBY P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002 May 15;287(19):2570e2581. 13 LEERTOUWER TC, PATTYNAMA PM, VAN DEN BERG-HUYSMANS A. Incidental renal artery stenosis in peripheral vascular disease: a case for treatment? Kidney Int 2001;59:1480e1483. 14 SACKS FM, SVETKEY LP, VOLLMER WM, APPEL LJ, BRAY GA, HARSHA D et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3e10. 15 COOK NR, CUTLER JA, OBARZANEK E, BURING JE, REXRODE KM, KUMANYIKA SK et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007;334:885. 16 COLLINS R, PETO R, MACMAHON S, HEBERT P, FIEBACH NH, EBERLEIN KA et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827e838. 17 PEPINE CJ, KOWEY PR, KUPFER S, KOLLOCH RE, BENETOS A, MANCIA G et al., INVEST investigators. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol 2006;47:547e551. 18 RADACK K, DECK C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769e1776. 19 SOLOMON SA, RAMSAY LE, YEO WW, PARNELL L, MORRIS-JONES W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991;303:1100e1104. 20 UBBINK DT, VERHAAR EE, LIE HK, LEGEMATE DA. Effect of betablockers on peripheral skin microcirculation in hypertension and peripheral vascular disease. J Vasc Surg 2003;38:535e540. 21 POLDERMANS D, BOERSMA E, BAX JJ, THOMSON IR, PAELINCK B, VAN DE VEN LL et al. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J 2001;22:1353e1358. 22 NARINS CR, ZAREBA W, MOSS AJ, MARDER VJ, RIDKER PM, KRONE RJ et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004;164:440e446. 23 TODA N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003;100:215e234. 24 WILLIAMS B, POULTER NR, BROWN MJ, DAVIS M, MCINNES GT, POTTER JF et al., British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139e185. 25 CG34. Hypertension: management in adults in primary care: pharmacological update. British Hypertension Society and National Institute for Healthcare Excellence; July 2007. Available from: www.nice.org.uk 26 ZANCHETTI A, JULIUS S, KJELDSEN S, MCINNES GT, HUA T, WEBER M et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006;24(11): 2163e2168. 27 MEHLER PS, COLL JR, ESTACIO R, ESLER A, SCHRIER RW, HIATT WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107:753e756. 28 OSTERGREN J, SLEIGHT P, DAGENAIS G, DANISA K, BOSCH J, QILONG Y et al., HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17e24. 29 HUNYADY L, CATT KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006;20:953e970. 30 VAN DE VEN PJ, BEUTLER JJ, KAATEE R, BEEK FJ, MALI WP, KOOMANS HA. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 1998;53:986e993. 31 DOMINICZAK A, ISLES C, GILLEN G, BROWN JJ. Angiotensin converting enzyme inhibition and renal insufficiency in patients with bilateral renovascular disease. J Hum Hypertens 1988;2:53e56. 32 BROWN MJ, PALMER CR, CASTAIGNE A, DE LEEUW PW, MANCIA G, ROSENTHAL T et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calciumchannel blocker or hypertension treatment (INSIGHT). Lancet 2000;356:366e372. 33 WILLIAMS G, DONALDSON RM. Nifedipine and nocturia. Lancet 1986;29(1):738. 34 Scottish Inter-Collegiate Guidelines Network. Diagnosis and management of peripheral arterial disease. SIGN guideline 89, October 2006. 35 Management of type 2 diabetes. Renal disease e prevention and early management. NICE Guidelines; Feb 2002. Available from: www.nice.org.uk 36 HADORN DC, BAKER D, HODGES JS, HICKS N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 1996;49: 749e754. 37 POWELL JT. Intermittent claudication: a plea for guidelines for medical management. Eur J Vasc Endovasc Surg 2007;33:451e452. 38 KHAN S, FLATHER M, MISTER R, DELAHUNTY N, FOWKES G, BRADBURY A et al. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. Eur J Vasc Endovasc Surg 2007; 33:442e450.|
Actions (login required)